Focus on unmet clinical needs, gather global innovation power, efficiently promote clinical development and commercialization, and empower the transformation of scientific research technology
R&D Introduction
Focus on unmet clinical needs and work with global biotechnology (or pharmaceutical) companies to jointly develop Global First (FIC) and Best in Class *(BIC) innovative products. Relying on our accumulated clinical and commercial capabilities and strong own cash flow, we are responsible for clinical development and commercial operations in China or specific markets, improving the efficiency of innovative drug research and development, and benefiting patients.
R&D Model
01
Equity investment in global Biotech and strategic cooperation with Bipharma
We are responsible for the clinical development, registration, marketing and commercialization of innovative products that are in the middle and late stages of clinical practice or have been approved for marketing. We are responsible for the clinical development, registration, marketing and commercialization of products in China and other authorized countries/regions to improve patients 'access to innovative drugs at home and abroad.
02
Equity investment/strategic cooperation with China Biotech with an innovative technology platform
Biotech is responsible for new drug discovery and preclinical research. We are responsible for the clinical development, registration, marketing and commercialization of products in China and other authorized countries/regions, improving the efficiency of research and development of innovative drugs in China, and accelerating the implementation of local innovation results
03
Independent customization and development of innovative products
Aiming at our own advantageous departments, we entrust CRO to provide product preclinical research services around new targets and hot targets. We independently promote the full life cycle management of innovative drugs and have global rights to our products.
Development
It has a four-in-one clinical development system and professional team that integrates medicine, clinical, pharmacovigilance and quality assurance to ensure that medical strategies are scientific and reasonable, clinical operations are efficient and compliant, and product safety risks are controllable.
Have proven rapid clinical enrollment capabilities：
220 patients were enrolled in tireqizumab injection within 2.5 months (including the Spring Festival)
384 patients were enrolled in 0.09% cyclosporine eye drops 4 months (including Spring Festival)
Methylene blue enteric-coated sustained-release tablets completed enrollment of 1,800 patients within 6 months (including Spring Festival)
Pipeline
We focus on cardiovascular and cerebrovascular, central nervous system, digestive, ophthalmology, skin, pediatrics and other diseases, and have established differentiated innovation pipelines.
China/Overseas has been marketed or is under review
China
Main approved areas**
ChinaUSEuropeanJapan
Nourishing yin and clearing heat, detoxifying and swelling. Used for oral inflammation caused by yin deficiency and excessive fire
Promote water, clear heat, and nourish yin, treat chronic glomerulonephritis, chronic pyelonephritis, nephrotic syndrome, renal failure, hydronephrosis, urinary tract infections and other diseases caused by water and heat accumulation, damage to yin and fluid, and failure of water and gas.
